-

DENTSPLY INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Dentsply Sirona, Inc. - XRAY

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Dentsply Sirona, Inc. (NasdaqGS: XRAY). Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit us at https://www.ksfcounsel.com/cases/nasdaqgs-xray/ to learn more.

On April 19, 2022, the Company disclosed that it “terminated” CEO Donald Casey “effective immediately,” and further revealed disappointing financial news including expected net sales of around $965 million, down 1.4% year over year and lower than the $1.02 billion expected by analysts and adjusted earnings per share of between $0.48 and $0.52, well below the consensus earnings estimate of $0.67. Then, on May 10, 2022, the Company disclosed an ongoing investigation by the Audit and Finance Committee of the Board of Directors, outside counsel and a forensic accounting firm into whether “former and current members of senior management” used improper means to achieve executive compensation goals and other matters relating to financial reporting.

The investigation concerns whether Dentsply and certain of its officers and/or directors have engaged in fraud, negligence or other unlawful business practices.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

Kahn Swick & Foti, LLC

NASDAQ:XRAY

Release Versions

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

More News From Kahn Swick & Foti, LLC

Super Micro Computer 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuits Against Super Micro Computer, Inc. - SMCI

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 26, 2026 to file lead plaintiff applications in securities class action lawsuits against Super Micro Computer, Inc. (“Super Micro” or the “Company”) (NasdaqGS: SMCI), if they purchased or otherwise acquired the Company’s securities between February 2, 2024 and March 19, 2026, inclusive (the “Cl...

Scotts Miracle-Gro Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of The Scotts Miracle-Gro Company - SMG

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into The Scotts Miracle-Gro Company (NYSE: SMG) (“Scotts” or the “Company”). On August 2, 2023, the Company disclosed disappointing financial results including a decline in quarterly sales for fiscal third quarter of 6%, a decline in gross margin by 420 basis points, as well a...

ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) (“ImmunityBio” or the “Company”), if they purchased or otherwise acquired the Company’s securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”)....
Back to Newsroom